Penumbra PEN Vascular — Revenue
Discontinued — last reported Q3 '23
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Penumbra in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Penumbra’s 10-Q, filed November 2, 2023, on SEC EDGAR. View the filing →
Ask your AI about Penumbra's vascular — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Penumbra's vascular — revenue?
- Penumbra (PEN) reported vascular — revenue of $99.54M in Q3 2023.
- How has Penumbra's vascular — revenue changed year-over-year?
- Penumbra's vascular — revenue increased by 10.2% year-over-year, from $90.32M to $99.54M.
- What does vascular — revenue mean?
- Total revenue generated from the sale of peripheral vascular medical devices.
- How do you interpret vascular — revenue?
- An increase indicates growing market adoption and successful commercialization of peripheral vascular product lines, while a decrease may signal increased competition or reduced demand for these specific interventions.
- How does vascular — revenue compare across companies?
- Comparable to peripheral vascular or interventional radiology segment revenues reported by medical device peers like Boston Scientific, Medtronic, or Abbott.